160145-82-4

Basic information

• Product Name: 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-10,11-didehydro-11-deoxy-6-O-methyl-3-oxo-erythromycin 2'-acetate
• Synonyms: 3-de[(2,6-dideoxy-3-c-methyl-3-o-methyl-a-l-ribo-hexopyranosyl)oxy]-10,11-didehydro-11-deoxy-6-o-methyl-3-oxo-erythromycin 2'-acetate;Telithromycin intermediate (6A);2 ∧ -OBEZOYL -3-O-DE [(2, 6-DIDEOXY-3-C-METHYL-3-O-METHYL-α-L-RIBOHEXOPYRANOSYL)OXY]-11-DEOXY-10,11-DIDEHYDRO-6-O-METHYL-3-OXO ERYTHROMYCIN;2'-OBEZOYL-3-O-DE[(2,6-DIDEOXY-3-C-METHYL-3-O-METHYL-ALPHA-L-RIBOHEXOPYRANOSYL)OXY]-11-DEOXY-10,11-DIDEHYDRO-6-O-METHYL-3-OXO-ERYTHROMYCIN;2 ''-OBEZOYL -3-O-DE [(2, 6-DIDEOXY-3-C-METHYL-3-O-METHYL-A-L-RIBOHEXOPYRANOSYL)OXY]-11-DEOXY-10,11-DIDEHYDRO-6-O-METHYL-3-OXO ERYTHROMYCIN
• CAS NO: 160145-82-4
• Molecular Formula: C₃₂H₅₃NO₁₀
• Molecular Weight: 673.839
• Mol File: 160145-82-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 707.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.14
• PKA: 10.93±0.70(Predicted)
• CAS DataBase Reference: 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-10,11-didehydro-11-deoxy-6-O-methyl-3-oxo-erythromycin 2'-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-10,11-didehydro-11-deoxy-6-O-methyl-3-oxo-erythromycin 2'-acetate(160145-82-4)
• EPA Substance Registry System: 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-10,11-didehydro-11-deoxy-6-O-methyl-3-oxo-erythromycin 2'-acetate(160145-82-4)

Safety Data

• Hazardous Substances Data: 160145-82-4(Hazardous Substances Data)

Usage

General Description

3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-10,11-didehydro-11-deoxy-6-O-methyl-3-oxo-erythromycin 2'-acetate is a complex chemical compound that belongs to the macrolide antibiotic class. It is a semi-synthetic derivative of erythromycin, with additional modifications to improve its stability and efficacy. The compound exhibits antimicrobial properties by inhibiting the synthesis of bacterial proteins, making it effective in treating a wide range of bacterial infections. The 2'-acetate moiety in the compound enhances its bioavailability and allows for more convenient dosing. As a potent antibiotic, this chemical has broad applications in medicine and healthcare for the treatment of various bacterial infections.

Upstream product

• 103461-66-1 2'-O-acetyl-6-O-methylerythromycin A 
• 152235-09-1 3-O-de-[(2,6-dideoxy-3-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-6-O-methyl-cyclic 11,12-carbonateerythromycin 2'-acetate 
• 143353-81-5 3-Ode-[(2,6-dideoxy-3-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-6-O-methylerythromycin 2￠-acetate 
• 118058-74-5 3-O-descladinosylclarithromycin 
• 81103-11-9 clarithromycin 
• 143353-85-9 3-O-de-[(2,6-dideoxy-3-methyl-3-O-methyl-α-D-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-cyclic 11,12-carbonate-erythromycin 2'-acetate 

Relevant articles and documents

A facile and scaleable synthesis of 3-O-decladinose-6-methyl-10,11- dehydrate-erythromycin-3-one-2′-acetate, an important intermediate for ketolide synthesis

A facile and scaleable synthetic process of compound 2, an important intermediate for synthesis of ketolide semisynthetic antibiotics, was developed starting from commercially available clathromycin with an overall yield of ～74%. This synthetic pathway wa

Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives

A series of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activity. The results showed that the majority of the target compounds displayed potent activity against erythromycin-susceptible S. pyogenes, erythromycin-resistant S. pneumoniae A22072 expressing the mef gene and S. pneumoniae AB11 expressing the mef and erm genes. Besides, most of the target compounds exhibited moderate activity against erythromycin-susceptible S. aureus ATCC25923 and B. subtilis ATCC9372. In particular, compounds 11a, 11b, 11c, 11e, 11f and 11h were found to exert favorable antibacterial activity against erythromycin-susceptible S. pyogenes with the MIC values of 0.015–0.125 μg/mL. Furthermore, compounds 10e, 11a, 11b and 11c showed superior activity against erythromycin-resistant S. pneumoniae A22072 with the MIC values of 0.25–0.5 μg/mL. Additionally, compound 11c was the most effective against all the erythromycin-resistant S. pneumoniae strains (A22072, B1 and AB11), exhibiting 8-, 8- and 32-fold more potent activity than clarithromycin, respectively.

Erythromycin A ketolide antibiotic derivatives containing quinoline substituent group, and preparation methods and applications thereof

The invention discloses a series of erythromycin A ketolide antibiotic derivatives containing quinoline substituent group, represented by a formula I. The invention also provides preparation methods and applications of the derivatives, and side-chain inte